KOSDAQMachinery405000

Plasmapp

₩3,275▼ 3.68%2026-11-18 close
Market Cap
₩17.6B
Turnover
₩2,993,815
Volume
935 shares
Shares out.
5.4M
PER
—
PBR
—
EPS
-₩2,548
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowed, but quarterly revenue recovery is not yet confirmed

Annual losses narrowed and capital impairment was resolved in 2025, but revenue fell and losses attributable to controlling shareholders widened through the first three quarters of 2026, so the turnaround is not yet visible in filed quarterly results.

  1. 1

    Annual revenue fell from KRW 13.3 billion in 2022 to KRW 8.48 billion in 2025, while the operating loss narrowed to KRW 7.6 billion from KRW 17.7 billion in 2024.

  2. 2

    Total equity at the end of 2025 was KRW 5.72 billion, and capital impairment that stood near 60% at the end of 2024 was fully resolved during 2025.

  3. 3

    Revenue in the first three quarters of 2026 was KRW 2.82 billion, KRW 2.84 billion and KRW 1.64 billion, and the third-quarter 2026 operating loss of KRW 2.08 billion was larger than the KRW 1.64 billion loss in the same quarter of 2025.

  4. 4

    A dental implant company signed a KRW 2.5 billion supply contract in March 2026, followed by a KRW 3.5 billion contract with QMED Master Distribution in June 2026, and both include exclusive sales rights and priority purchase rights.

  5. 5

    The large-capacity sterilizer STERI 700 has received MFDS approval, and FDA 510(k) clearance and CE certification are targeted for the first half of 2027.

02

Business structure

Plasmapp is a medical device company that sells low-temperature plasma sterilizers, implant surface treatment equipment and consumables.

Its main businesses are the STERLINK low-temperature plasma sterilization solution, the ACTILINK implant surface regeneration and activation solution, and consumables such as sterilization pouches and sterilants.

In the first quarter of 2026, equipment accounted for 60.0% of revenue and consumables for 37.5%, and exports made up 41.5%, according to an independent research report dated July 2026. The same report described the model as one in which equipment sales lead to recurring consumables revenue.

The customer base was centered on dental clinics, but the company said the larger STERI 700 sterilizer, which has MFDS approval, would open ophthalmology and orthopedic practices that handle large instruments. The STERI 700 chamber is about four times wider than the company's existing 7L and 14L small sterilizers.

In ophthalmology, the company is testing products with Alcon. Overseas, Plasmapp has signed a supply contract with QMED Master Distribution in Florida, and it has set up US and European subsidiaries and signed agreements with partners in 12 countries.

Competition comes from several equipment makers in the low-temperature sterilization and implant surface treatment markets for dental and eye care. Because equipment placements and consumables move together, the pace of installed-base growth largely determines the size of consumables revenue.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩2.2B-₩1.6B−75.9%
2025Q4₩4.2B-₩1B−24.1%
2026Q1₩2.8B-₩2.2B−76.2%
2026Q2₩2.8B-₩2.3B−80.4%
2026Q3₩1.6B-₩2.1B−126.7%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩13.3B-₩17.4B-₩17.7B−130.4%−188.7%286.9%
2023₩12.9B-₩20.6B-₩18.8B−159.3%−232.6%392.5%
2024₩10.1B-₩17.7B-₩20.8B−174.2%−459.1%463.6%
2025₩8.5B-₩7.6B-₩6.6B−89.6%−115.2%259.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Revenue on a filed basis moved from KRW 13.3 billion in 2022 to KRW 12.9 billion in 2023 (down 2.9% year on year), KRW 10.1 billion in 2024 (down 21.5%) and KRW 8.48 billion in 2025 (down 16.3%).

Revenue declined for three consecutive years from 2023 through 2025, with 2022 the largest year and 2025 the smallest in the 2022–2025 period. A Korean trade report said revenue had risen from KRW 6.4 billion in 2021 to KRW 13.3 billion in 2022 before the 2023 decline.

The operating loss widened from KRW 17.4 billion in 2022 to KRW 20.6 billion in 2023, then narrowed to KRW 17.7 billion in 2024 and KRW 7.6 billion in 2025, and the operating margin improved from -174.2% in 2024 to -89.6% in 2025.

The company attributed the cost reduction to a slimmer fixed-cost structure, better outsourcing and purchasing terms, and workforce efficiency, and said the operating loss fell by more than KRW 10 billion.

The loss attributable to controlling shareholders went from KRW 17.7 billion in 2022 to KRW 20.8 billion in 2024 and then KRW 6.59 billion in 2025, while the net loss including non-controlling interests was KRW 6.59 billion in 2025.

Capital impairment that was near 60% at the end of 2024 was fully resolved during 2025, and the debt ratio fell from 463.6% to 259.3%, with total liabilities of KRW 14.8 billion. Operating cash outflow narrowed from -KRW 16 billion in 2022 and -KRW 22 billion in 2023 to -KRW 4.52 billion in 2025.

On a quarterly basis, revenue of KRW 4.19 billion in the fourth quarter of 2025 rose 94.0% from the prior quarter and was the highest quarter in 2025.

Revenue then fell to KRW 2.82 billion in the first quarter of 2026, KRW 2.84 billion in the second quarter and KRW 1.64 billion in the third quarter, which was down 42.4% from the prior quarter and 24.1% from a year earlier.

The operating loss has been reported in each of the five quarters from the third quarter of 2025 through the third quarter of 2026.

The loss attributable to controlling shareholders reached KRW 2.84 billion in the third quarter of 2026, the largest of the five quarters, and totaled KRW 8.77 billion over the last four quarters. In all five quarters, the loss attributable to controlling shareholders was larger than the operating loss.

05

Industry analysis

In low-temperature plasma sterilization, the main barrier to overseas sales is certification. The company said it is working through country-specific regulatory steps with the aim of obtaining FDA 510(k) clearance and CE marking in the first half of 2027.

Because certification timing sets when overseas sales can begin, the pace of North American and European revenue growth depends on the regulatory schedule. Domestically, the customer base is moving from dental clinics toward ophthalmology and orthopedic practices that need to sterilize large instruments.

The company said it holds 174 patents and 45 certifications including FDA clearance and sells in about 55 countries, but this was its own description at the time of its 2022 listing and cannot be verified as a current market share figure.

Equipment revenue can swing from quarter to quarter depending on contract and installation timing, while consumables are generally described as the steadier layer that builds on the installed base.

Revenue peaked in the fourth quarter of 2025 and then moved in mixed directions, down in the first quarter of 2026, slightly up in the second and down in the third.

Overseas, the US distributor QMED holds a two-year priority negotiation right for the Mexican ophthalmology market, which gives Plasmapp a base for expansion into Latin America. Ophthalmology demand is the common growth thread in both domestic and overseas plans, which defines the company's position in the sector.

06

Outlook

The company said it plans to begin domestic sales of the STERI 700 after receiving MFDS approval. In ophthalmology, it is testing products with Alcon and pursuing new customers.

An independent research report from July 2026 said the company plans to launch the large-capacity STERI 700 sterilizer and the Plasma Endo root canal treatment device. The company said in June 2026 that PLASMA ENDO was in the approval process with a target launch in the third quarter of 2026.

That target date has passed, so the launch status and when it will show up in revenue are the next items to check. The QMED agreement covers a minimum purchase of 390 units, including 300 STERLINK U510 units and 90 STERI 700 units, worth about KRW 3.5 billion, with deliveries on a quarterly schedule.

The company said its annual active trading customers more than doubled year on year and that repurchase rates in key customer groups recovered to above 70%.

The independent research report said that if 2026 revenue of KRW 18 billion and breakeven were achieved, the company could ease concerns about its listing status and could be revalued as a plasma medtech platform company.

However, revenue in the first three quarters of 2026 stayed below the fourth-quarter 2025 level of KRW 4.19 billion, and that scenario would require fourth-quarter revenue to rise sharply above each quarter of 2026 so far. The FDA and CE outcomes in the first half of 2027 will mark a key point for when overseas sales can expand.

07

Valuation

PER
—
PBR
—
ROE
-136.6%
EPS
-₩2,548
BPS
—
Dividend per share
₩0

Because losses attributable to controlling shareholders have continued across the last four quarters, the price-to-earnings ratio cannot be calculated, and the company does not pay a dividend. With no earnings-based multiple available, valuation is examined against equity and revenue.

Total equity at the end of 2025 was KRW 5.72 billion, and the market capitalization is well above that figure, which places the stock in a range of substantial premium to net asset value.

The August 2026 third-party share issuance increased the number of shares outstanding, so each share represents a smaller stake in the company. On a revenue basis, quarterly sales in 2026 have stayed below the fourth-quarter 2025 peak, so any sales multiple depends on how the quarterly trend develops.

An independent research report from July 2026 said that revaluation as a plasma medtech platform would be possible if KRW 18 billion in 2026 revenue and breakeven were achieved. That view depends on those conditions, and filed results need to confirm them before it can inform a view on the current valuation level.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Cost restructuring and a rebuilt equity base

The 2025 operating loss narrowed to KRW 7.6 billion from KRW 17.7 billion in 2024, and the operating margin improved to -89.6% from -174.2%. The company cited a slimmer fixed-cost base, better outsourcing and purchasing terms, and workforce efficiency as the drivers. Capital impairment was fully resolved during 2025, which left total equity positive at the end of the year.

New products and certification timeline

The large-capacity STERI 700 has MFDS approval and is set for domestic sales, with the customer base widening toward ophthalmology and orthopedics. PLASMA ENDO had a target launch in the third quarter of 2026.

If FDA 510(k) clearance and CE certification are obtained on the targeted schedule in the first half of 2027, overseas sales become possible, so whether these milestones reach revenue is the key test for the bull case.

Overseas contracts and export mix

The QMED agreement commits a minimum purchase of 390 units, including 300 STERLINK U510 and 90 STERI 700 units, worth about KRW 3.5 billion. It also includes a priority negotiation right for the Mexican ophthalmology market and a North American priority purchase right for the STERI 700.

A KRW 2.5 billion contract with a dental implant company in March 2026 also carried exclusive sales and priority purchase rights. Exports made up 41.5% of revenue in the first quarter of 2026.

09

Bear factors

Quarterly revenue decline and a wider operating loss

Third-quarter 2026 revenue of KRW 1.64 billion fell 42.4% from the prior quarter and 24.1% from a year earlier. The operating loss of KRW 2.08 billion in the same quarter was larger than the KRW 1.64 billion loss in the third quarter of 2025.

Revenue has not sustained the recovery seen after the fourth quarter of 2025 peak, and filed results do not yet show how much new-product revenue is contributing.

Wider losses to controlling shareholders and a thin equity cushion

The loss attributable to controlling shareholders reached KRW 2.84 billion in the third quarter of 2026, the largest of the last five quarters, and totaled KRW 8.77 billion over the last four quarters.

Against total equity of KRW 5.72 billion at the end of 2025, total liabilities were KRW 14.8 billion and the debt ratio was 259.3%. With a thin equity cushion, dependence on additional outside financing could remain high, which is the core of the bear case.

Frequent financing and share dilution

The August 2026 third-party share issuance added 1,535,088 common shares, bringing the total listed shares to 5,373,532. Stock options for 121,900 shares were approved at the March 2026 general meeting, and the total outstanding grants on an unexercised basis are 300,387 shares.

In June 2026, the stock was designated for investment caution twice because of concentrated trading in a small number of accounts.

10

Risk factors

Financing and dilution risk

Convertible bonds and rights offerings have recurred since the listing, and a third-party share issuance was completed in August 2026. The lock-up on the new shares runs through August 13, 2027.

The largest shareholder has also provided joint guarantees for the repayment of the company's convertible bonds, which points to continued reliance on outside support.

Certification and launch timing risk

FDA 510(k) clearance and CE certification are targeted for the first half of 2027, and any delay would push back overseas sales. PLASMA ENDO also had a third-quarter 2026 launch target, and the timing of its revenue contribution is not yet visible in quarterly results.

Whether new products translate into exercised priority purchase rights under the overseas contracts remains to be seen in upcoming disclosures.

Trading volatility and reliance on the largest shareholder risk

The stock was designated for investment caution on June 2, 2026 due to concentrated buying by a small number of accounts, and again on June 8, 2026 due to concentrated selling. In one three-day window, the share price moved -24.39%.

Continued support from the largest shareholder has been cited as a factor behind financial stability, and a reduction in that support would weaken that factor.

11

What to watch next

  1. Late March 2027

    This is the filing window for the 2026 annual report. Confirmed 2026 annual revenue, operating loss and loss attributable to controlling shareholders, and whether fourth-quarter revenue recovered to the KRW 4.19 billion level of the fourth quarter of 2025, are the items to check.

  2. By May 15, 2027

    This is the deadline for the first-quarter 2027 quarterly report. The next items to check are whether first-quarter revenue exceeds KRW 2.82 billion from the first quarter of 2026 and whether the operating loss falls from the KRW 2 billion range seen through 2026.

  3. First half of 2027

    The key item is whether FDA 510(k) clearance and CE certification are obtained. Certification would allow North American and European sales to begin, while a delay would push back the timing of overseas revenue growth.

  4. August 13, 2027

    This is the end of the lock-up period for the 1,535,088 shares issued in the August 2026 third-party allotment. The volume of shares that can be traded after this date could affect supply and demand for the stock.

12

Overall view

Plasmapp narrowed its 2025 operating loss to KRW 7.6 billion, resolved capital impairment and reshaped its cost base.

However, revenue in the first three quarters of 2026 was KRW 2.82 billion, KRW 2.84 billion and KRW 1.64 billion, below the KRW 4.19 billion peak of the fourth quarter of 2025, and the operating loss and the loss attributable to controlling shareholders widened across five consecutive loss-making quarters.

On the positive side are the STERI 700 approval, the PLASMA ENDO development and contracts with QMED and a dental implant company that broaden the revenue base.

On the negative side are the KRW 8.77 billion loss attributable to controlling shareholders over the last four quarters, a thin equity base and reliance on outside financing, including the August 2026 share issuance.

On valuation, no earnings-based multiple is available, so the comparison runs through equity and revenue. The 2026 revenue scenario of KRW 18 billion would require fourth-quarter revenue to rise sharply.

The next items to check are the annual figures in the 2026 annual report, the FDA and CE outcomes in the first half of 2027, and quarterly revenue in the first quarter of 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. biotimes.co.kr
  2. view.asiae.co.kr
  3. asiae.co.kr
  4. jobplanet.co.kr
  5. rapportian.com
  6. sedaily.com
  7. m.irgo.co.kr
  8. hkn24.com
  9. pharm.edaily.co.kr
  10. m.news.nate.com
  11. topstarnews.net
  12. m.news.nate.com
  13. topstarnews.net
  14. topstarnews.net
  15. topstarnews.net

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis